CL
ENGNW icon

CSS LLC’s enGene Therapeutics Warrants ENGNW Stock Holding History

CSS LLC’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.7K Hold
16,895
– – ﹤0.01% 869
2025
Q4 		$50K Hold
16,895
– – ﹤0.01% 901
2025
Q3 		$12K Hold
16,895
– – ﹤0.01% 959
2025
Q2 		$13.9K Hold
16,895
– – ﹤0.01% 927
2025
Q1 		$10.1K Hold
16,895
– – ﹤0.01% 880
2024
Q4 		$14.2K Hold
16,895
– – ﹤0.01% 932
2024
Q3 		$32.9K Hold
16,895
– – ﹤0.01% 762
2024
Q2 		$20.1K Sell
16,895
-3,105
-16% -$9.94K ﹤0.01% 820
2024
Q1 		$104K Sell
20,000
-7,000
-26% -$21.3K 0.01% 705
2023
Q4 		$22.9K Buy
+27,000
New +$20.8K ﹤0.01% 747

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ICM
Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

CSS LLC's ENGNW Position: Q1 2026 in Review

CSS LLC held its enGene Therapeutics Warrants (ENGNW) position steady in Q1 2026 at 16,895 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #869.

CSS LLC first reported a position in ENGNW in Q4 2023 and has held it in 10 quarters since. The position peaked at $104K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

  • CSS LLC held 16,895 shares of enGene Therapeutics Warrants worth $42.7K as of Q1 2026.
  • CSS LLC left its enGene Therapeutics Warrants share count unchanged in Q1 2026.
  • enGene Therapeutics Warrants made up ﹤0.01% of CSS LLC's portfolio in Q1 2026, its #869 holding.
  • CSS LLC first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 10 quarters since.
  • CSS LLC's enGene Therapeutics Warrants position peaked at $104K in Q1 2024.
  • 11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.